Compare Warner Music Group Corp (WMG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Warner Music Group Corp vs Zimmer Biomet Holdings Inc — how do they compare? Warner Music Group Corp trades at $28.86 (market cap $15.12B), while Zimmer Biomet Holdings Inc trades at $89.53 (market cap $16.95B). The key difference: Warner Music Group Corp and Zimmer Biomet Holdings Inc are close in size by market cap, and Warner Music Group Corp pays the higher dividend (2.77%). Which is the better fit depends on your goals — on Pluang, investors hold Warner Music Group Corp for 96 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| WMG | ZBH | |
|---|---|---|
Market Cap | $15.12B | $16.95B |
Volume | 2,966,414 | 2,505,240 |
Sector | Media | Health |
52-Week High | $34.72 | $103.98 |
52-Week Low | $23.65 | $79.58 |
Typical Hold Time | 96 Days | 89 Days |
Enterprise Value | $19.42B | $24.02B |
Dividend Yield | 2.77% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WMG trades at $28.875, up 2.54% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.38, beating expectations, and has a strong analyst consensus of 'Buy' with a $39.50 price target. Recent news highlights AI partnerships and licensing renewals as growth catalysts.
Outlook remains positive due to streaming growth and AI initiatives, but risks include competitive pressures and margin volatility. The stock offers upside potential from current levels if execution continues, though investor caution is warranted near-term given elevated RSI levels.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
